- Home
- FSBC vs PLRX Comparison
FSBC vs PLRX Comparison
Compare FSBC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSBC
- PLRX
- Stock Information
- Founded
- FSBC 2002
- PLRX 2015
- Country
- FSBC United States
- PLRX United States
- Employees
- FSBC N/A
- PLRX N/A
- Industry
- FSBC Banks
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FSBC Finance
- PLRX Health Care
- Exchange
- FSBC Nasdaq
- PLRX Nasdaq
- Market Cap
- FSBC 565.6M
- PLRX 77.3M
- IPO Year
- FSBC 2021
- PLRX 2020
- Fundamental
- Price
- FSBC $30.07
- PLRX $1.40
- Analyst Decision
- FSBC Buy
- PLRX Hold
- Analyst Count
- FSBC 4
- PLRX 10
- Target Price
- FSBC $34.75
- PLRX $9.79
- AVG Volume (30 Days)
- FSBC 55.6K
- PLRX 1.6M
- Earning Date
- FSBC 07-23-2025
- PLRX 08-06-2025
- Dividend Yield
- FSBC 2.64%
- PLRX N/A
- EPS Growth
- FSBC N/A
- PLRX N/A
- EPS
- FSBC 2.27
- PLRX N/A
- Revenue
- FSBC $124,973,000.00
- PLRX N/A
- Revenue This Year
- FSBC $25.86
- PLRX N/A
- Revenue Next Year
- FSBC $15.15
- PLRX N/A
- P/E Ratio
- FSBC $13.35
- PLRX N/A
- Revenue Growth
- FSBC 11.14
- PLRX N/A
- 52 Week Low
- FSBC $22.22
- PLRX $1.10
- 52 Week High
- FSBC $35.13
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- FSBC 64.34
- PLRX 54.68
- Support Level
- FSBC $29.63
- PLRX $1.13
- Resistance Level
- FSBC $30.65
- PLRX $1.27
- Average True Range (ATR)
- FSBC 0.79
- PLRX 0.11
- MACD
- FSBC 0.21
- PLRX 0.02
- Stochastic Oscillator
- FSBC 86.10
- PLRX 90.00
About FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.